Wave crashes on DMD data as investors await Huntington’s readout
Wave drops DMD programs as data raise concerns about its stereopure oligonucleotides
Wave’s decision to discontinue its two Duchenne muscular dystrophy programs raised broader investor concerns about the company’s stereopure oligonucleotide platform and sent shares down more than 50% on Monday. Another readout for the platform in a second indication before year-end should provide more clues about the platform’s potential.
Wave Life Sciences Ltd. (NASDAQ:WVE) fell $20.81 (55%) to $16.79 on